Biomea Fusion Valuation Multiples

Biomea Fusion Overview

About Biomea Fusion

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program’s drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib’s potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Founded

2017

HQ

Employees

106

Website

biomeafusion.com

Sectors

BiopharmaceuticalsBioTechDeepTech

Financials (LTM)

Revenue: —

EBITDA: ($79M)

EV

$105M

Valuation Multiples

Multiples.vc

Start free trial

Biomea Fusion Financials

Biomea Fusion reported last 12-month revenue of — and negative EBITDA of ($79M).

In the same LTM period, Biomea Fusion generated — in gross profit, ($79M) in EBITDA losses, and had net loss of ($66M).

Biomea Fusion P&L

In the most recent fiscal year, Biomea Fusion reported revenue of — and EBITDA of ($80M).

Biomea Fusion expects next 12-month revenue of XXX and NTM EBITDA of XXX

Biomea Fusion Stock Performance

Biomea Fusion has current market cap of $159M, and enterprise value of $105M.

Biomea Fusion's stock price is $2.20.

Biomea Fusion Valuation Multiples

Biomea Fusion trades at (1.3x) EV/EBITDA.

Biomea Fusion Financial Valuation Multiples

As of April 20, 2026, Biomea Fusion has market cap of $159M and EV of $105M.

Equity research analysts estimate Biomea Fusion's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Biomea Fusion has a P/E ratio of (2.4x).

Biomea Fusion Margins & Growth Rates

Biomea Fusion's revenue in the last fiscal year grew by —.

Biomea Fusion's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.8M for the same period.

Biomea Fusion Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Biomea Fusion M&A Activity

Biomea Fusion acquired XXX companies to date.

Last acquisition by Biomea Fusion was on XXXXXXXX, XXXXX. Biomea Fusion acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Biomea Fusion Investment Activity

Biomea Fusion invested in XXX companies to date.

Biomea Fusion made its latest investment on XXXXXXXX, XXXXX. Biomea Fusion invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).